PreviPharma Consulting GmbH is an internationally active research and development company. Together with partners in plasma fractionation, plasma donation centers, and technology suppliers, our team develops new medical and technological solutions from plasma donation to the finished therapy product. Plasma industry including recombinant proteins has grown to more than $ 20 billion of annual sales. However, only few more than 10 out of approximately 2500 plasma proteins are presently available for therapeutic use. Significant market potential exceeding the present market is left untapped. PreviPharma’s MIP (Medical Innovation Platform) has identified several early stage drug candidates and created significant data packages. All of them are developed for indications with substantial market potential. These include various therapeutic areas such as hematology, infectious disease, gastrointestinal indications, neurology, and inflammation.